Discover how VFLO's recent reconstitution reshaped its sector allocation, maintaining quality and value. Click here to read ...

JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,100 and keeps an Overweight rating on the shares. The firm ...

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...

The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the ...

Intech Investment Management LLC raised its position in 2seventy bio, Inc. (NASDAQ:TSVT – Free Report) by 41.1% during the fourth quarter, according to the company in its most recent 13F filing with ...

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $130,880.12 today based ...

Japan’s Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent ...

Biotech company Regeneron (REGN) and French pharmaceutical giant Sanofi (SNY) today announced that Japan has granted ...

BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...